DK1849470T4 - Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor - Google Patents

Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor Download PDF

Info

Publication number
DK1849470T4
DK1849470T4 DK06712292.9T DK06712292T DK1849470T4 DK 1849470 T4 DK1849470 T4 DK 1849470T4 DK 06712292 T DK06712292 T DK 06712292T DK 1849470 T4 DK1849470 T4 DK 1849470T4
Authority
DK
Denmark
Prior art keywords
alpha
trifluorthymidin
indeholder
cancerlægemiddel
thymidin
Prior art date
Application number
DK06712292.9T
Other languages
Danish (da)
English (en)
Other versions
DK1849470T3 (en
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1849470(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1849470T3 publication Critical patent/DK1849470T3/en
Publication of DK1849470T4 publication Critical patent/DK1849470T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06712292.9T 2005-01-26 2006-01-25 Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor DK1849470T4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
DK1849470T3 DK1849470T3 (en) 2017-08-14
DK1849470T4 true DK1849470T4 (en) 2024-04-02

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06712292.9T DK1849470T4 (en) 2005-01-26 2006-01-25 Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor

Country Status (21)

Country Link
EP (1) EP1849470B2 (OSRAM)
JP (1) JP5576591B2 (OSRAM)
KR (1) KR101468216B1 (OSRAM)
AU (1) AU2006209547C1 (OSRAM)
BE (1) BE2017C028I2 (OSRAM)
CA (1) CA2594713A1 (OSRAM)
CY (2) CY1119393T1 (OSRAM)
DK (1) DK1849470T4 (OSRAM)
ES (1) ES2630002T5 (OSRAM)
FI (1) FI1849470T4 (OSRAM)
FR (1) FR17C1028I2 (OSRAM)
HU (2) HUE033306T2 (OSRAM)
LT (2) LT1849470T (OSRAM)
LU (1) LUC00036I2 (OSRAM)
NL (1) NL300889I2 (OSRAM)
PL (1) PL1849470T5 (OSRAM)
PT (1) PT1849470T (OSRAM)
RU (1) RU2394581C2 (OSRAM)
SI (1) SI1849470T2 (OSRAM)
TW (1) TWI362265B (OSRAM)
WO (1) WO2006080327A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
PE20120631A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
PE20141650A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
AU2012295841B2 (en) * 2011-08-16 2015-12-10 Les Laboratoires Servier Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EP2829611A4 (en) 2012-03-14 2015-12-02 Nisshin Pharma Inc SULFURAMINOUS-SUSTAINABLE COMPOSITION
RS57913B1 (sr) 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
SG11201406550QA (en) * 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
HUE041687T2 (hu) * 2013-03-27 2019-05-28 Taiho Pharmaceutical Co Ltd Antitumor szer, amely tartalmaz kis dózisú irinotekan-hidroklorid-hidrát-ot
LT2979701T (lt) * 2013-03-27 2020-11-10 Taiho Pharmaceutical Co., Ltd. Priešnavikinis agentas, įskaitant irinotekano hidrochlorido hidratą
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
UA121538C2 (uk) 2013-09-06 2020-06-25 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування злоякісного новоутворення
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6871868B2 (ja) * 2016-01-08 2021-05-19 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
WO2017135412A1 (ja) 2016-02-05 2017-08-10 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100424934B1 (ko) 1995-03-29 2004-07-27 다이호야쿠힌고교 가부시키가이샤 우라실유도체및이를함유하는항종양효과증강제및항종양제
CA2238331C (en) * 1996-09-24 2003-02-25 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa

Also Published As

Publication number Publication date
CY2017029I1 (el) 2018-02-14
NL300889I2 (nl) 2018-01-16
TW200637562A (en) 2006-11-01
PL1849470T3 (pl) 2017-11-30
LUC00036I2 (OSRAM) 2017-12-01
LTC1849470I2 (lt) 2019-10-25
WO2006080327A1 (ja) 2006-08-03
JP5576591B2 (ja) 2014-08-20
FI1849470T4 (fi) 2024-03-22
ES2630002T5 (es) 2024-09-19
HUS1700032I1 (hu) 2017-09-28
LT1849470T (lt) 2017-07-25
TWI362265B (en) 2012-04-21
LTPA2017024I1 (lt) 2017-08-10
SI1849470T1 (sl) 2017-10-30
PT1849470T (pt) 2017-09-22
AU2006209547C1 (en) 2022-04-07
NL300889I1 (nl) 2017-08-14
SI1849470T2 (sl) 2024-05-31
JPWO2006080327A1 (ja) 2008-06-19
PL1849470T5 (pl) 2024-06-10
BE2017C028I2 (OSRAM) 2025-09-10
KR101468216B1 (ko) 2014-12-03
EP1849470A4 (en) 2010-12-08
EP1849470B1 (en) 2017-06-21
EP1849470A1 (en) 2007-10-31
HUE033306T2 (hu) 2017-11-28
CY2017029I2 (el) 2018-02-14
RU2394581C2 (ru) 2010-07-20
EP1849470B2 (en) 2024-03-20
ES2630002T3 (es) 2017-08-17
KR20070104559A (ko) 2007-10-26
DK1849470T3 (en) 2017-08-14
AU2006209547A1 (en) 2006-08-03
AU2006209547B2 (en) 2011-05-26
RU2007132181A (ru) 2009-03-10
FR17C1028I1 (OSRAM) 2017-09-29
FR17C1028I2 (fr) 2018-11-02
CA2594713A1 (en) 2006-08-03
CY1119393T1 (el) 2018-02-14
LUC00036I1 (OSRAM) 2017-10-02

Similar Documents

Publication Publication Date Title
DK1849470T4 (en) Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
AP2204A (en) 4-phenylamino-quinazolin-6-yl-amides.
ATE503759T1 (de) 7-ä2-ä4-(6-fluor-3-methyl-1,2-benzisoxazol-5-yl - 1-piperazinylüethylü-2-(1-propinyl)-7h-pyrazolo
PL1969815T3 (pl) Układ do korzystnie mobilnego użytkowania systemu ERP i dalszych aplikacji
EP1844567A4 (en) PASSWORDS
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
AP2850A (en) Selective havester
GB0522534D0 (en) Windturbine
GB0506800D0 (en) New uses
GB0505823D0 (en) Boardmate, boardmate adjustable
GB0504761D0 (en) Alfatie, Coliawel, Omaatie
HU0500500D0 (en) Ball for moving, used for general purposes
GB0503644D0 (en) Catstep I
GB0522528D0 (en) PPJS (peeJays) promotional-paperweigh-jambs
GB0502736D0 (en) Demopod (studiopod)
GB0522257D0 (en) H-rtm-roha(c)
GB0523210D0 (en) Blokbusta, heatbusta & trappa (variations on common principle)
GB0521911D0 (en) Alpha zetic
GB2440780B (en) The rula
AU2005900030A0 (en) Glowbal, Glowves, Moonstik
GB0500851D0 (en) C.f.m.
AP2005003379A0 (en) Lamp.
GB0526628D0 (en) C.I. Max
GB0509859D0 (en) VirtualTrolley.Com